RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pacira Biosciences Stock

Pacira Biosciences Revenue 2024

Pacira Biosciences Revenue

707.17 M USD

Ticker

PCRX

ISIN

US6951271005

WKN

A1H68T

In 2024, Pacira Biosciences's sales reached 707.17 M USD, a 4.77% difference from the 674.98 M USD sales recorded in the previous year.

The Pacira Biosciences Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e1.1642,34
2028e1.0546,79
2027e0.954,45
2026e0.8358,81
2025e0.6772,65
2024e0.7169,33
20230.6772,64
20220.6770,11
20210.5474,11
20200.4372,70
20190.4274,66
20180.3474,24
20170.2969,33
20160.2860,17
20150.2571,16
20140.260,80
20130.0935,98
20120.0417,65
20110.02-7,01
20100.0115,75
20090.0218,00
20080.01-25,18
20070.01-14,46
20060.01-27,42
20050.0227,14

Pacira Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pacira Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pacira Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pacira Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pacira Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pacira Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pacira Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pacira Biosciences’s growth potential.

Pacira Biosciences Revenue, EBIT and net profit per share

DatePacira Biosciences RevenuePacira Biosciences EBITPacira Biosciences Net Income
2029e1.16 B undefined0 undefined236.67 M undefined
2028e1.05 B undefined392.21 M undefined274.32 M undefined
2027e900.49 M undefined340.82 M undefined233.7 M undefined
2026e833.73 M undefined293.72 M undefined192.57 M undefined
2025e674.9 M undefined244.78 M undefined153.98 M undefined
2024e707.17 M undefined185.88 M undefined143.01 M undefined
2023674.98 M undefined87.32 M undefined41.96 M undefined
2022666.8 M undefined70.9 M undefined15.9 M undefined
2021541.5 M undefined132.8 M undefined42 M undefined
2020429.6 M undefined60.5 M undefined145.5 M undefined
2019421 M undefined35.7 M undefined-11 M undefined
2018337.3 M undefined17.5 M undefined-500,000 undefined
2017286.6 M undefined-20.1 M undefined-42.6 M undefined
2016276.4 M undefined-32 M undefined-37.9 M undefined
2015249 M undefined9.5 M undefined1.9 M undefined
2014197.7 M undefined-5.2 M undefined-13.7 M undefined
201385.6 M undefined-53.3 M undefined-63.9 M undefined
201239.1 M undefined-49.3 M undefined-52.3 M undefined
201115.7 M undefined-36.1 M undefined-43.3 M undefined
201014.6 M undefined-22.7 M undefined-27.1 M undefined
200915 M undefined-28.5 M undefined-31.7 M undefined
200813.9 M undefined-45.4 M undefined-41.9 M undefined
20078.3 M undefined-26 M undefined-36.2 M undefined
200612.4 M undefined-28.2 M undefined-37.3 M undefined
200521 M undefined-28.3 M undefined-34.3 M undefined

Pacira Biosciences stock margins

The Pacira Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pacira Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pacira Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pacira Biosciences's sales revenue. A higher gross margin percentage indicates that the Pacira Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pacira Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pacira Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pacira Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pacira Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pacira Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pacira Biosciences Margin History

Pacira Biosciences Gross marginPacira Biosciences Profit marginPacira Biosciences EBIT marginPacira Biosciences Profit margin
2029e72.64 %0 %20.44 %
2028e72.64 %37.42 %26.18 %
2027e72.64 %37.85 %25.95 %
2026e72.64 %35.23 %23.1 %
2025e72.64 %36.27 %22.82 %
2024e72.64 %26.29 %20.22 %
202372.64 %12.94 %6.22 %
202270.11 %10.63 %2.38 %
202174.11 %24.52 %7.76 %
202072.7 %14.08 %33.87 %
201974.66 %8.48 %-2.61 %
201874.24 %5.19 %-0.15 %
201769.33 %-7.01 %-14.86 %
201660.17 %-11.58 %-13.71 %
201571.16 %3.82 %0.76 %
201460.8 %-2.63 %-6.93 %
201335.98 %-62.27 %-74.65 %
201217.65 %-126.09 %-133.76 %
2011-7.01 %-229.94 %-275.8 %
201015.75 %-155.48 %-185.62 %
200918 %-190 %-211.33 %
2008-25.18 %-326.62 %-301.44 %
2007-14.46 %-313.25 %-436.14 %
2006-27.42 %-227.42 %-300.81 %
200527.14 %-134.76 %-163.33 %

Pacira Biosciences Aktienanalyse

What does Pacira Biosciences do?

Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for use in anesthesia, pain management, and oncology. The company was founded in 2007 and is headquartered in Parsippany, New Jersey. Pacira Biosciences' success story began with the development of EXPAREL, a long-acting painkiller based on liposome technology. EXPAREL was the first product approved by the US Food and Drug Administration (FDA) for local infiltration to relieve pain after surgery. Since then, the company has expanded its portfolio and now offers products for use in oncology and other areas of medicine. Pacira Biosciences' business model is based on the manufacture and sale of high-quality, innovative drugs both in the US and internationally. Product development is done in close collaboration with doctors and patients to ensure that patient needs are met and medical requirements are fulfilled. The company operates in three main divisions: anesthesia, pain management, and oncology. In the anesthesia division, Pacira Biosciences offers the product EXPAREL, which is used for local infiltration into the surgical wound to relieve pain after surgery. EXPAREL is a liposomal, slow-release painkiller that enables patients to recover without pain and minimizes the risk of opioid dependence. In the pain management division, Pacira Biosciences has developed the products bupivacaine and meloxicam, which are used in the treatment of acute and chronic pain. These products provide a safe and effective alternative to opioids for pain management. In the oncology division, the company has introduced the product ONIVYDE, which is used for the treatment of patients with metastatic pancreatic cancer. ONIVYDE was developed in collaboration with the FDA and has proven to be effective in combating cancer. In addition to offering products, Pacira Biosciences works closely with doctors, hospitals, and government agencies to ensure that the products are used safely and effectively. The company also conducts extensive research and development activities to develop new products and improve existing ones. In conclusion, Pacira Biosciences Inc. is a leading international company specializing in innovative pharmaceuticals in the fields of anesthesia, pain management, and oncology. The company is actively working on developing new innovative products and offering doctors and patients a safe and effective alternative to traditional pain medications. With its strong commitment to the healthcare industry, Expard will continue to advance the development of new and therapeutic agents to better assist patients. Answer: Pacira Biosciences Inc. is an international pharmaceutical company specializing in the development and manufacture of innovative drugs for anesthesia, pain management, and oncology. They are known for their product EXPAREL, a long-acting painkiller approved by the FDA for local infiltration after surgery. The company operates in three divisions and works closely with healthcare professionals and government agencies to ensure safe and effective use of their products. They are committed to advancing healthcare through research and development. Pacira Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Pacira Biosciences's Sales Figures

The sales figures of Pacira Biosciences originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Pacira Biosciences’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Pacira Biosciences's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Pacira Biosciences’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Pacira Biosciences stock

How much revenue did Pacira Biosciences generate this year?

Pacira Biosciences has achieved a revenue of 707.17 M USD this year.

How much was the turnover of the company Pacira Biosciences compared to the previous year?

The revenue of Pacira Biosciences has increased by 4.77% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Pacira Biosciences?

The revenue of Pacira Biosciences is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Pacira Biosciences measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Pacira Biosciences so important for investors?

The revenue of Pacira Biosciences is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Pacira Biosciences pay?

Over the past 12 months, Pacira Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacira Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacira Biosciences?

The current dividend yield of Pacira Biosciences is .

When does Pacira Biosciences pay dividends?

Pacira Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacira Biosciences?

Pacira Biosciences paid dividends every year for the past 0 years.

What is the dividend of Pacira Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacira Biosciences located?

Pacira Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacira Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacira Biosciences from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Pacira Biosciences pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Pacira Biosciences in the year 2023?

In the year 2023, Pacira Biosciences distributed 0 USD as dividends.

In which currency does Pacira Biosciences pay out the dividend?

The dividends of Pacira Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pacira Biosciences

Our stock analysis for Pacira Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacira Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.